Opdivo (nivolumab) is a cancer medicine that works with your immune system to interfere with the growth and spread of cancer cells in the body. This monoclonal antibody blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
Indication and Usage:
Metastatic melanoma-patients with BRAF V600 mutation-positive unresectable
Metastatic Non-Small Cell Lung Cancer
Classical Hodgkin Lymphoma
Squamous Cell Carcinoma Of The Head And Neck
Side Effects:
Common side effects of Opdivo includes:
atigue.
rash.
itching.
cough.
upper respiratory tract infection.
swelling of the extremities.
shortness of breath.
muscle pain.
Dosage form & Strength:
Opdivo (nivolumab) 240mg/24ml injection
Opdivo (nivolumab) 100mg/10ml injection
Opdivo (nivolumab) 40mg/4ml injection
Rasso Swiss Pharma is a wholesaler, distributor, supplier for Opdivo (nivolumab).